Artificial intelligence company Owkin announced on September 2, local time, that it has signed a license agreement with German pharmaceutical company Boehringer Ingelheim. The latter will use Owkin's AI research platform and patient data to accelerate the development of drugs for cancer and immune-related diseases. The parties did not disclose the financial terms of the agreement.

Zhitongcaijing · 2d ago
Artificial intelligence company Owkin announced on September 2, local time, that it has signed a license agreement with German pharmaceutical company Boehringer Ingelheim. The latter will use Owkin's AI research platform and patient data to accelerate the development of drugs for cancer and immune-related diseases. The parties did not disclose the financial terms of the agreement.